Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Preliminary pilot data suggest that the iPACES neuro-exergaming system can positively impact cognitive function in older adults with mild cognitive impairment or early-stage dementia. Changes in salivary biomarkers were moderately associated with improved cognition. Further research via ongoing clinical trials aims to validate these findings for broader application in brain health and aging populations.
"Further research is needed, but these pilot data provide preliminary indications to suggest neuro-exergaming can impact cognitive function...and as such may provide an effective and practical way to promote healthy aging."
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on iPACES.